Tuesday, Jounce Therapeutics announced it had received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce's equity at a per-share price of $1.80 in cash.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,